Haemonetics (NYSE: HAE) reported Q1 EPS of $0.50, $0.04 better than the analyst estimate of $0.46. Revenue for the quarter came in at $229 million versus the consensus estimate of $219.35 million.

GUIDANCE:

Haemonetics sees FY2022 EPS of $2.60-$3.00, versus the consensus of $2.78.

• The Company affirmed its GAAP total revenue growth guidance of 13 – 18% and organic revenue growth guidance issued on May 13, 2021

For earnings history and earnings-related data on Haemonetics (HAE) click here.